These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18563575)

  • 61. Rapid throughput solubility screening method for BCS class II drugs in animal GI fluids and simulated human GI fluids using a 96-well format.
    Guo J; Elzinga PA; Hageman MJ; Herron JN
    J Pharm Sci; 2008 Apr; 97(4):1427-42. PubMed ID: 17724660
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus.
    Garbacz G; Cadé D; Benameur H; Weitschies W
    Eur J Pharm Sci; 2014 Jun; 57():264-72. PubMed ID: 24021609
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3.
    Schönherr D; Wollatz U; Haznar-Garbacz D; Hanke U; Box KJ; Taylor R; Ruiz R; Beato S; Becker D; Weitschies W
    Eur J Pharm Biopharm; 2015 May; 92():155-70. PubMed ID: 25758123
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Microencapsulation of chlorpheniramine maleate-resin particles with crosslinked chitosan for sustained release.
    Huang RG; Schwartz JB; Ofner CM
    Pharm Dev Technol; 1999 Jan; 4(1):107-15. PubMed ID: 10027219
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
    Lindenberg M; Kopp S; Dressman JB
    Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1501-19. PubMed ID: 21919807
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing.
    Reddy NH; Patnala S; Kanfer I
    AAPS PharmSciTech; 2017 Feb; 18(2):424-431. PubMed ID: 27038483
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
    Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
    Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
    Yang SG
    Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preparation of Sustained Release Formulation of Verapamil Hydrochloride Using Ion Exchange Resins.
    Allaboun H; Alkhamis KA; Al-Nimry SS
    AAPS PharmSciTech; 2023 May; 24(5):114. PubMed ID: 37127745
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oral biopharmaceutics-current status and identified gaps of understanding.
    Lennernäs H; Abrahamsson P; Langguth B
    Eur J Pharm Sci; 2014 Jun; 57():98. PubMed ID: 24508580
    [No Abstract]   [Full Text] [Related]  

  • 75. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
    Charalabidis A; Sfouni M; Bergström C; Macheras P
    Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional wood's apparatus.
    Avdeef A; Tsinman O
    Pharm Res; 2008 Nov; 25(11):2613-27. PubMed ID: 18648912
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
    Macheras P; Iliadis A; Melagraki G
    Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FIP Guidelines for Dissolution Testing of Solid Oral Products.
    Friedel HD; Brown CK; Barker AR; Buhse LF; Keitel S; Kraemer J; Morris JM; Reppas C; Sperry DC; Sakai-Kato K; Stickelmeyer MP; Shah VP
    J Pharm Sci; 2018 Dec; 107(12):2995-3002. PubMed ID: 30148985
    [TBL] [Abstract][Full Text] [Related]  

  • 79. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs.
    Flanagan T
    Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.